ShanghaiMay 15, 2026 /PRNewswire/ — BPD Biopharmaceutical Process Development Conference, an industry benchmark event focusing on the entire lifecycle from biopharmaceutical process development to commercialization, has been deeply rooted in the CMC field since its inception in 2017 by Enmore Medical. It has become a highly influential annual event in China’s biopharmaceutical CMC sector. After years of dedicated development, the BPD Annual Conference, centered in Shanghai, has achieved leapfrog growth, with its 2025 edition surpassing 5,000 attendees.
Shanghai BPD Annual Conference
Over the years, the Shanghai BPD Annual Conference has been hosted by Enmore Medical, with WuXi Biologics as the strategic host, and co-hosted by Duoning Biotechnology, Lishui Technology, and WuXi XDC. Bringing together leading industry technology representatives and high-quality supply chain enterprises, it has created an efficient platform for exchange, cooperation, innovation, and development for biopharmaceutical CMC process partners through in-depth technical discussions, high-end business networking, and precise resource connections. It has also laid a solid foundation for cooperation in upgrading industry process technology and achieving commercial success.
2026 BPD Global Strategic Layout
In 2026, building on the solid foundation of the Shanghai Annual Conference, the BPD brand will further deepen its global strategic layout. Centered around five key conferences — BPD Beijing – BPD USA – BPD Shanghai – BPD Singapore – BPD Chengdu — it aims to build a biopharmaceutical CMC exchange network covering both domestic and international markets. Using process innovation as a link, it will connect global biopharmaceutical innovation resources and empower the high-quality development of the global biopharmaceutical industry!
- BPD Beijing (May 21-22): Co-organized by Ganlee Pharmaceutical and Yimiao Shenzhou, focusing on CMC policies and practical cases in the North China region. Expected to gather 1,500+ attendees and 60+ speakers, building a core platform for process exchange in North China. Leading industry representatives from companies such as BeiGene, Hengrui Medicine, Sinovac Biotech, and Chia Tai Tianqing Shunxin Pharmaceutical have confirmed participation.
- BPD USA (June 21): Deeply integrated with BIOCHINA USA, featuring a dedicated session with 100+ participants. Invited heavyweight speakers from leading industry companies including Amgen, Gilead Science, StellarHealth Consulting, Bambusa Therapeutics, Yilian Biotechnology, Qide Pharmaceutical, Huode Bio, Jingtai Technology, and JW Therapeutics will share experiences in biopharmaceutical technology and commercial translation. The focus is on CMC going global, helping Chinese companies connect with US biopharmaceutical companies and technical experts.
- BPD Shanghai (August 6-7): The 9th Annual CMC Process Professionals Conference, with a scale of 5,000+ and 150+ invited speakers. It focuses on process breakthroughs across all tracks and global layout, using innovative molecule R&D and CMC content to engage early-stage research audiences, and leveraging overseas content and international speakers to attract C-level executives. Leading pharmaceutical companies such as Sanofi, Henlius, Innovent Group, Qilu Pharmaceutical, GeneScience Pharmaceuticals, Fosun Kite, IASO Bio, and Juventas Cell Therapy are actively participating to build a collaborative exchange platform for process decision-makers. Additionally, BPD Shanghai 2026 will newly feature the AI for Pharma Conference, covering AI’s cutting-edge applications from early R&D to process production, empowering the new future of biopharmaceuticals across the entire chain.
- BPD Singapore (September 22-23): Hosted by Enmore Medical, with WuXi XDC again serving as co-organizer. Expected to gather 500+ attendees and 50+ speakers, delving into the Southeast Asian market with a focus on process capacity cooperation and regional compliance, serving as a “springboard” for Chinese pharmaceutical companies going global. Currently, MNCs such as J&J and Gilead have confirmed attendance, along with representatives from institutions and companies including Singapore’s A*STAR BTI and Pharmagend, Indonesia’s BPOM, Thailand’s Nouvogenes Therapeutics, and China’s Suzhou Sirnaomics and Buchang Pharmaceuticals.
- BPD Chengdu (November 5-6): Featuring Kelun-Biotech as a special co-organizer, focusing on CMC practical cases in the Southwest China region to strengthen regional industrial synergy. With a conference scale of 1,000+ attendees and 50+ speakers, it continues to expand BPD Chengdu’s industry influence. Currently, upstream biopharmaceutical suppliers and service providers such as Yingsaisi, Opmei, Weipu, Pfanstiehl, and Laodechuang have reserved exhibition booths, jointly creating a full-industry-chain cooperation and exchange platform.
BPD Brand Global Cooperation Launch
The BPD Conference has always been positioned with the core mission of “Focusing on CMC, Integrating Globally, Sharing Industry Development”. After nine years of dedicated effort, it has become a key link connecting governments, pharmaceutical companies, research institutions, and upstream/downstream enterprises. In 2026, the BPD brand will continue to collaborate with industry leaders, deeply connect domestic and international industrial resources, and promote process technology exchange, industrial chain synergy, and global cooperation. The BPD full series of conferences is now officially opening its global cooperation channels, sincerely inviting more industry organizations to join hands in building a diverse and open global biopharmaceutical process cooperation platform, uniting global process innovation forces.